Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.23.2
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 10,582 7,341 19,393 14,734
General and administrative 3,870 3,332 9,155 7,439
Operating expenses 14,452 10,673 28,548 22,173
Other income/(expense):        
Interest income 326 111 748 133
Foreign exchange loss (3) (3) (5) (6)
Total other income 323 108 743 127
Net loss (14,129) (10,565) (27,805) (22,046)
Other comprehensive loss:        
Unrealized (loss) gain on available-for-sale securities (1) (37) 3 (37)
Total comprehensive loss $ (14,130) $ (10,602) $ (27,802) $ (22,083)
Basic loss per common share (in dollars per share) $ (2.27) $ (1.72) $ (4.47) $ (3.59)
Diluted loss per common share (in dollars per share) $ (2.27) $ (1.72) $ (4.47) $ (3.59)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 6,234 6,150 6,219 6,149
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 6,234 6,150 6,219 6,149